alzheimer-s-dise
Instructed caregiver there is no cure for Alzheimer's disease, so the chief goals of treatment are to: maintain quality of life, maximize function in daily activities, enhance cognition, mood and behavior foster a safe environment promote social engagement, as appropriate. Caregiver verbalized.
Instructed in new medication Aricept to manage moderate dementia of the Alzheimer type. In addition, warned of possible S/E such as headache, insomnia, dizziness, fatigue, depression, abnormal dreams, somnolence, seizures, tremor, irritability, paresthesia, aggression, vertigo, ataxia, restlessness, abnormal crying, nervousness, aphasia, syncope, pain, chest pain, hypertension, vasodilation, atrial fibrillation, hot flashes, hypotension, cataract, blurred vision, eye irritation, sore throat, nausea, diarrhea, vomiting, anorexia, fecal incontinence, GI bleeding, bloating, epigastric pain, frequent urination, ecchymosis, weight loss, dehydration, muscle cramps, arthritis, toothache, bone fracture, dyspnea, bronchitis, pruritus, urticaria, diaphoresis, influenza, and increased libido. The drug does not alter the underlying degenerative disease but can temporarily stabilize or relieve symptoms. Effective therapy depends on taking drug at regular intervals. Instructed to take drug in the evening, just before bedtime. Immediately report significant adverse effects or changes in overall health status. Inform health care team that patient is taking drug before he receives anesthesia. Avoid OTC cold or sleep remedies because of the potential for increased anticholinergic effects.
SN taught that Parkinson's disease is the second-most common neurodegenerative disorder, after Alzheimer's disease. While classically considered a movement disorder, there is a growing recognition that Parkinson's disease produces a wide variety of non motor symptoms as well.
Encouraged patient verbalization regarding fears and concerns about disease and prognosis. Taught patient how to help with reality orientation and stimulation.
SN instructed patient on new medication Namenda. SN instructed patient that namenda extended-release capsules are approved for the treatment of moderate to severe Alzheimer's disease, and that the most common side effects associated with namenda treatment are headache, diarrhea, and dizziness. Understanding was verbalized
SN to instruct caregiver on disease process management, medication regimen and management of behavior disturbances.